This study was aimed to evaluate the effects of polysaccharide peptides (PsP) of Ganoderma lucidum as anti inflammation, anti oxidant, anti diabetic and anti lipid in stable angina pectoris patients.
Design and Method:
This is a quasi clinical trial experimental study on 34 Stable Angina patients in Saiful Anwar General Hospital was determined based on ESC Stable CAD guidelines, with pre-test and post-test design without control. Parameter measured were TNF alfa, IL-6, MDA, SOD, HbA1c, Fasting glucose and Total cholesterol. The patients were given PsP 750 mg/day in divided dose for 90 days, while continuing the previous medications as directed by guidelines. The data was analyzed by paired t-test for parametric data and Wilcoxon test for non-parametric data.
After PSP administration we found significantly reduce the level of TNF alfa level from 11444 ± 2352.70 to 476.13 ± 482.99 (p = 0.000), IL-6 level from 294.70 ± 123.28 to 24.41 ± 21.45 (p = 0.000), MDA level from 95.63 ± 21.27 to 44,84 ± 50,95 (p = 0.000), increased SOD level from 3.41 ± 0,46 to 5,97 ± 4,19, HbA1c from 6.59 ± 3.05 to 5.62 ± 1.41 (p = 0.009), fasting glucose level reduced from 113.08 ± 12.44 mg/dl to 97.95 ± 6.22 mg/dl (p = 0.342) and total cholesterol level reduced from 205,49 ± 48,49 mg/dl to 182,11 ± 73,81 mg/dl (p = 0.081).
Ganoderma lucidum polysaccharide peptides have distinctive effect on anti inflammation, anti oxidant, anti diabetic and anti lipid in stable angina pectoris and promising as additional drug in the treatment of coronary artery disease caused by atherosclerotic process.